Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTransplantation ChimeraBone MarrowTissue DonorsGraft vs Leukemia EffectWhole-Body IrradiationBone Marrow CellsPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaHistocompatibilityTreatment OutcomeHistocompatibility TestingGraft SurvivalRecurrenceMyeloablative AgonistsGraft vs Tumor EffectRetrospective StudiesChimerismHematologic DiseasesLeukemia, Myeloid, AcuteStem CellsAnemia, AplasticMyelodysplastic SyndromesImmunosuppressive AgentsVidarabineRemission InductionCord Blood Stem Cell TransplantationLymphocyte TransfusionHLA AntigensHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsTransplantation, IsogeneicLiver TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSiblingsCombined Modality TherapyTime FactorsTransplantation ImmunologySurvival RateHematopoiesisCytomegalovirus InfectionsSurvival AnalysisAcute DiseaseCyclophosphamideLymphocyte DepletionT-LymphocytesDisease-Free SurvivalMice, Inbred C57BLSevere Combined ImmunodeficiencyFollow-Up StudiesOpportunistic InfectionsMultiple MyelomaCystitisFlow CytometryMinor Histocompatibility AntigensLeukemic InfiltrationHematopoietic Stem Cell MobilizationLeukemia, MyeloidAntigens, CD34ImmunosuppressionKidney TransplantationNeoplasm, ResidualAntilymphocyte SerumCell DifferentiationSalvage TherapyLymphoproliferative DisordersBone and BonesGraft RejectionAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusImmunocompromised HostBlood Group IncompatibilityPrognosisFatal OutcomeBronchiolitis ObliteransRisk FactorsCyclosporineBone Marrow PurgingCytarabineCell TransplantationColony-Forming Units AssayCell LineageMelphalanMesenchymal Stem Cell TransplantationMycosesPrimary MyelofibrosisCells, CulturedLymphoma, Non-HodgkinRadiation ChimeraGanciclovir